Mayzent® is the commercial brand name of Siponimod Tablets, an orally active sphingosine-1-phosphate receptor modulator developed by Novartis. It selectively binds to S1P receptors on lymphocytes to reduce lymphocyte infiltration into the central nervous system and alleviate neuroinflammatory injury.
Main Indications
Treatment of adult patients with secondary progressive multiple sclerosis with active inflammatory lesions.
Clinical Research
Global pivotal phase III trial confirmed that siponimod effectively reduces the risk of confirmed disability progression and lowers relapse frequency in patients with secondary progressive multiple sclerosis;
Long-term follow-up studies demonstrated sustained clinical benefits and a manageable safety profile during long-term oral administration;
Asian subgroup analysis showed consistent efficacy and tolerability results consistent with the overall global population.
Common Side Effects
Severe but important risks: Bradycardia, atrioventricular block, hepatic injury, increased infection risk, macular edema;
Common mild adverse reactions: Headache, hypertension, alopecia, dizziness, nausea and fatigue.
Approval Status in China
Original drug Mayzent® (Siponimod Tablets) was officially approved for marketing in China in 2020, with the specification of 0.25 mg. It is currently a prescription drug included in China’s Category B medical insurance catalogue.
Buy Mayzent (Siponimod Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
